Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials (vol 113, pg 833, 2018)

Singh Siddharth; Proudfoot James; Xu Ronghui; Sandborn William J.

首页> 外文期刊>The American Journal of Gastroenterology >Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials (vol 113, pg 833, 2018)

【24h】

Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials (vol 113, pg 833, 2018)

机译：肥胖和反应炎症性肠病患者的嗜血项：临床试验中个体参与者数据的汇总分析（Vol 113，PG 833,2018）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The American Journal of Gastroenterology》 |2019年第6期|共1页
作者
Singh Siddharth; Proudfoot James; Xu Ronghui; Sandborn William J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials (vol 113, pg 833, 2018) [J] . Singh Siddharth, Proudfoot James, Xu Ronghui, The American Journal of Gastroenterology . 2019,第6期

机译：肥胖和反应炎症性肠病患者的嗜血项：临床试验中个体参与者数据的汇总分析（Vol 113，PG 833,2018）
2. Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials (vol 24, pg 2278, 2018) [J] . Singh Siddharth, Proudfoot James, Xu Ronghui, Inflammatory bowel diseases . 2019,第10期

机译：肥胖对炎症性肠病疾病的短期和中期结果的影响：对英夫利昔单抗临床试验安慰剂臂的合并分析（Vol 24，PG 2278,2018）
3. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials (vol 113, pg 1197, 2018) [J] . Singh Siddharth, Proudfoot James, Dulai Parambir S., The American Journal of Gastroenterology . 2019,第6期

机译：伴随溃疡性结肠炎患者伴随的5-氨基水溶液的益处无益于生物疗法：从临床试验中汇总了个体参与者数据的分析（Vol 113，PG 1197,2018）
4. Analysis of Microbiome Data across Inflammatory Bowel Disease Patients [C] . Wisittipanit Nuttachat, Rangwala Huzefa, Gillevet Patrick Machine Learning and Applications and Workshops (ICMLA), 2011 10th International Conference on . 2011

机译：炎症性肠病患者的微生物组数据分析
5. Serum and Fecal Biomarkers Predict Response to Infliximab Therapy in Pediatric Patients with Inflammatory Bowel Disease [D] . Kim, Jochebed. 2020

机译：血清和粪便生物标志物预测对炎症肠病小儿患者的英夫利昔单抗疗法的反应
6. Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials [O] . Siddharth Singh, James Proudfoot, Ronghui Xu, -1

机译：肥胖对炎性肠病短期和中期结果的影响：英夫利昔单抗临床试验安慰剂组的汇总分析
7. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials [O] . Siddharth Singh, James Proudfoot, Ronghui Xu, 2018

机译：肥胖和反应炎症性肠疾病患者中的嗜荷敏性和反应：临床试验的个体参与者数据的汇总分析

Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials (vol 113, pg 833, 2018)

著录项

相似文献

相关主题

期刊订阅